Innovative Cancer Therapy Bio-Orthogonal Catalysis
Discover the groundbreaking work on bio-orthogonal catalysis for cancer therapy by TEVA Pharmaceutical Industries LTD in partnership with Marie Skłodowska-Curie Actions. Learn about the team, their roles, and the planned secondments and trainings within the project. Explore the role of ESR3 in oral nano delivery formulation design and characterization, with a focus on enzyme-responsive dendrons and lipid/polymer-based nano formulations. Stay updated on the latest developments in this cutting-edge research field.
Uploaded on | 0 Views
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Bio-ortogonal catalysis for cancer therapy TEVA Presentation Mid-Term Check Meeting Edinburgh, 5th June 2019 Teva Pharmaceutical Industries LTD Innovative Training Networks (ITN) Marie Sk odowska-Curie Actions H2020-MSCA-ITN-2017 (THERACAT-765497)
Teva Leading Generic Medicines 1000+ Launches in 2017 Top 3 position in 25 markets 1 in 7 Rx in the US Strong Gx growth in Japan and LatAm 550+ therapies 1800+ Molecules #1 in first-to-files 1 in 8 Rx in the UK Teva Leading Specialty Brands Innovative Training Networks (ITN) Marie Sk odowska-Curie Actions H2020-MSCA-ITN-2017 (THERACAT-765497)
Teva Team Principal Investigator Bianca Avramovitch, PhD Teva Coordinator, Academic Affairs and Networks Tal Yoetz, PhD Analytical Technologies Specialist Yousif Ayoub, PhD Formulation Specialists Aviram Spernath, PhD Tamar Gordon, PhD Krishna Vippala ESR3 Fellow Macro Molecules Specialist Turi Komlosh, PhD CMC Development Specialist (chemistry & manufacturing controls) Tal Hasson, PhD Chemistry Specialist Sharon Gazal, PhD Innovative Training Networks (ITN) Marie Sk odowska-Curie Actions H2020-MSCA-ITN-2017 (THERACAT-765497)
Role within the network ESR3: Oral nano delivery Formulation design and characterization Research Synthesize enzyme-responsive hydrophobic dendrons according to procedures developed by Prof. Amir (TAU) and to modify it to target the specific indication Develop high resolving methods for characterizing the species developed in collaboration with TAU and any other interested consortium partners. Develop methods which should monitor the processes involved and researched Evaluate the new species in biological systems. Development of lipid/polymer-based nano formulation in lab scale Extensive physicochemical characterization of the NPs NPs GMP Manufacturing in larger scale (scale-up) depending on the previous steps success Innovative Training Networks (ITN) Marie Sk odowska-Curie Actions H2020-MSCA-ITN-2017 (THERACAT-765497)
Role within the network Planned secondments and trainings: At Teva : ESR 4 TUE industrial formulation of SCPN (M30, 3 months) ESR 10 BAS - encapsulate catalyst in lipid NP (M36, 3 months) ESR 13 TAU (Satchi Fainaro) oral formulations (M36, 3 months) ESR 3 - TEVA. At IBEC: NP imaging (Month 18 21, 4 months) At TUE SAXS characterization of NP (Month 30, 3months) Planned Trainings: Sept 26, 2019, Basel Innovative Training Networks (ITN) Marie Sk odowska-Curie Actions H2020-MSCA-ITN-2017 (THERACAT-765497)
